Insider Transactions in Q4 2022 at Biocryst Pharmaceuticals Inc (BCRX)
Insider Transaction List (Q4 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 29
2022
|
Jon P Stonehouse President & CEO |
BUY
Bona fide gift
|
Indirect |
10,000
+33.33%
|
-
|
|
Dec 29
2022
|
Jon P Stonehouse President & CEO |
SELL
Bona fide gift
|
Direct |
10,000
-0.98%
|
-
|
|
Dec 19
2022
|
Anthony Doyle Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
34,000
+14.66%
|
-
|
|
Dec 19
2022
|
Charles K Gayer Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
34,000
+12.16%
|
-
|
|
Dec 19
2022
|
Michael L Jones Exec. Director, Finance - PAO |
BUY
Grant, award, or other acquisition
|
Direct |
5,900
+26.16%
|
-
|
|
Dec 19
2022
|
Jon P Stonehouse President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
127,500
+11.16%
|
-
|
|
Dec 19
2022
|
Helen M. Thackray Chief R&D Officer |
BUY
Grant, award, or other acquisition
|
Direct |
81,000
+27.43%
|
-
|
|
Dec 19
2022
|
Alane P Barnes Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
34,000
+12.75%
|
-
|
|
Dec 15
2022
|
Jon P Stonehouse President & CEO |
SELL
Open market or private sale
|
Direct |
14,100
-1.56%
|
$141,000
$10.9 P/Share
|
|
Dec 15
2022
|
Alane P Barnes Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
4,175
-2.06%
|
$41,750
$10.88 P/Share
|
|
Dec 15
2022
|
Michael L Jones Exec. Director, Finance - PAO |
SELL
Open market or private sale
|
Direct |
445
-3.97%
|
$4,450
$10.9 P/Share
|
|
Dec 15
2022
|
Charles K Gayer Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
6,100
-2.8%
|
$61,000
$10.9 P/Share
|
|
Dec 15
2022
|
Anthony Doyle Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,700
-3.36%
|
$57,000
$10.9 P/Share
|
|
Dec 15
2022
|
Helen M. Thackray Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
3,125
-2.29%
|
$31,250
$10.89 P/Share
|
|
Dec 02
2022
|
Jon P Stonehouse President & CEO |
SELL
Open market or private sale
|
Direct |
82,656
-8.4%
|
$991,872
$12.8 P/Share
|
|
Dec 02
2022
|
Jon P Stonehouse President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
82,656
+7.75%
|
$82,656
$1.42 P/Share
|
|
Dec 01
2022
|
Jon P Stonehouse President & CEO |
SELL
Open market or private sale
|
Direct |
214,917
-19.24%
|
$2,793,921
$13.0 P/Share
|
|
Dec 01
2022
|
Jon P Stonehouse President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
214,917
+16.14%
|
$214,917
$1.42 P/Share
|
|
Dec 01
2022
|
Michael L Jones Exec. Director, Finance - PAO |
SELL
Open market or private sale
|
Direct |
8,600
-43.44%
|
$111,800
$13.01 P/Share
|
|
Dec 01
2022
|
Michael L Jones Exec. Director, Finance - PAO |
BUY
Exercise of conversion of derivative security
|
Direct |
8,600
+30.28%
|
$8,600
$1.42 P/Share
|
|
Nov 30
2022
|
Theresa Heggie Director |
BUY
Grant, award, or other acquisition
|
Direct |
421
+1.34%
|
$5,473
$13.36 P/Share
|
|
Nov 30
2022
|
Robert Alexander Ingram Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,497
+1.51%
|
$19,461
$13.36 P/Share
|
|
Nov 30
2022
|
Alan G Levin Director |
BUY
Grant, award, or other acquisition
|
Direct |
842
+4.54%
|
$10,946
$13.36 P/Share
|
|
Nov 30
2022
|
Vincent Milano Director |
BUY
Grant, award, or other acquisition
|
Direct |
421
+1.33%
|
$5,473
$13.36 P/Share
|
|
Nov 14
2022
|
Yarlagadda S Babu Chief Discovery Officer |
SELL
Open market or private sale
|
Direct |
31,515
-9.55%
|
$409,695
$13.88 P/Share
|
|
Nov 14
2022
|
Yarlagadda S Babu Chief Discovery Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+14.15%
|
$100,000
$1.42 P/Share
|